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Abstract
Background: Although Nigeria has a large HIV epidemic, the impact of HIV on cancer in Nigerians is unknown.
Methods: We conducted a registry linkage study using a probabilistic matching algorithm among a cohort of HIV
positive persons registered at health facilities where the Institute of Human Virology Nigeria (IHVN) provides HIV
prevention and treatment services. Their data was linkedt od a t af r o m2 0 0 9t o2 0 1 2i nt h eA b u j aC a n c e rR e g i s t r y .
Match compatible files with first name, last name, sex, date of birth and unique HIV cohort identification numbers
were provided by each registry and used for the linkage analysis. We describe demographic characteristics of the
HIV clients and compute Standardized Incidence Ratios (SIRs) to evaluate the association of various cancers with
HIV infection.
Results: Between 2005 and 2012, 17,826 persons living with HIV (PLWA) were registered at IHVN. Their median
age (Interquartile range (IQR)) was 33 (27–40) years; 41% (7246/17826) were men and 59% (10580/17826) were
women. From 2009 to 2012, 2,029 clients with invasive cancers were registered at the Abuja Cancer Registry.
The median age (IQR) of the cancer clients was 45 (35–68) years. Among PLWA, 39 cancer cases were
identified, 69% (27/39) were incident cancers and 31% (12/39) were prevalent cancers. The SIR (95% CI) for
the AIDS Defining Cancers were 5.7 (4.1, 7.2) and 2.0 (0.4, 3.5), for Kaposi Sarcoma and Cervical Cancer
respectively.
Conclusion: The risk of Kaposi Sarcoma but not Cervical Cancer or Non-Hodgkin’s Lymphoma, was significantly
increased among HIV positive persons, compared to the general population in Nigeria.
Keywords: HIV, Cancer, AIDS-cancer match, Registry linkage, Nigeria
Background
HIV infection is associated with an increased risk of
diverse cancers. Classically, the Centers for Disease
Control and Prevention (CDC) designated Kaposi sarcoma
(KS) cervical cancer (CC) and non-Hodgkin’sl y m p h o m a
(NHL) as AIDS defining cancers (ADCs) because of the
association of these cancers with increased risk of HIV
infection. The advent of highly active antiretroviral therapy
(HAART) in 1996 has led to significant reduction in the
incidence and prevalence of these ADCs [1]. Nevertheless,
the risk of ADCs remains high in many low and middle in-
come countries (LMIC) where there are significant
populations with HIV infection who are not on treatment.
In contrast, in countries with mature HIV epidemics and
combination ART, there is a modest increase in other
cancers which have been designated non-AIDS defining
cancers (NADCs), including anal, head and neck, lung and
liver cancers, Hodgkin’s lymphoma, and melanoma [2-6].
Most of the studies conducted to investigate the rela-
tionship between HIV infection and malignancies in
sub-Saharan Africa to date have largely emanated from
East and Southern Africa and this may not accurately
reflect the pattern of AIDS associated malignancies in
Africa [7-13]. Furthermore only one of these African
studies was population based and it showed that about
* Correspondence: sna094@mail.harvard.edu
1Department of Nutrition, Harvard School of Public Health, 677 Huntington
Avenue, Boston, MA, USA
2Office of Strategic Information and Research, Institute of Human Virology,
Abuja, Nigeria
Full list of author information is available at the end of the article
© 2014 Akarolo-Anthony et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Akarolo-Anthony et al. Infectious Agents and Cancer 2014, 9:1
http://www.infectagentscancer.com/content/9/1/170% of cancers occurring in the studied HIV infected
population in Uganda were ADCs. The risks of five other
NADCs - cancers of the kidney, thyroid, uterus, conjunc-
tiva and Hodgkin’s lymphoma - were also increased [12].
Apart from such systematic studies, other reports from
Africa were based on hospital or pathology case series
with a majority of such studies emanating from Nigeria,
West Africa. Table 1 is a summary of the AIDS-associated
malignancy studies among adults in Africa from January
2001 to December 2012.
Nigeria being the most populous country in Africa,
with an estimated population of 170,123,740 (41% of
whom are below age 15 years) in 2012 [23] and the third
highest population of persons living with HIV/AIDS
(PLWA) in the world, is expected to bear a significant
proportion of the projected AIDS associated cancer
burden in Africa. The incidence and prevalence of cancer
among PLWA in Nigeria is not known. This lack of
data hampers the ability to formulate sound policy for
clinical and public health intervention. The successful
implementation of record-linkage studies in different parts
of the world, e.g. Uganda, India, suggests that this may
be a feasible approach to the study of AIDS associated
cancers in Nigeria.
We conducted this study to evaluate the spectrum of
cancers diagnosed among PLWA in Nigeria using the
record-linkage technique.
Results
We excluded 1103 (6%) and 75 (4%) clients from the
HIV and cancer registries respectively, because they had
missing data on age, date of diagnosis or several demo-
graphic variables. The participant flow is summarized in
Figure 1 and the characteristics of the population study
are summarized in Table 2. Between 2005 and 2012,
17,826 clients were registered by the HIV registry. The
median age (Interquartile range (IQR)) of the HIV clients
was 33 (27–40) years. On average, ~2000 clients were
registered with the HIV registry per year, of whom 41%
(7,246/17,826) were men and 59% (10,580/17,826) were
women. From 2009 to 2012, 2,029 clients with invasive
cancers were registered at the cancer registry. The
median age (IQR) of the cancer clients was 45 (35–68)
years. On average, ~500 clients were registered with
the cancer registry/year, 36% (728/2,029) of these were
men and 64% (1,301/2,029) were women.
Among PLWA, 39 cancer cases were identified, 31%
(12/39) were prevalent cancers and 69% (27/39) were
incident cancers. All the prevalent cancers occurred from
34 months before to 2 months after registration, while
44% (12/27) and 56% (15/27) of the incident cancers
occurred in the early and late incident periods respect-
ively. Also, 26% (10/39) of the cancers identified were
among men and 74% (29/39) among women. The ADCs
identified were KS and CC; while the NADCs were breast,
ovary, prostate, liver, anal, eye and other non-epithelial
skin cancers. The ADCs and NADCs accounted for
41% (16/39) and 59% (23/39) of the cancers among
PLWA respectively. The SIR (95% CI) for the ADCs were
5.7 (4.1, 7.2) and 2.0 (0.4, 3.5), for KS and CC respectively.
We observed 9 cases of breast cancer, but the SIR was not
significantly increased (SIR 1.6, 95% CI 0.2, 3.0). Table 3
shows the types, ICD and morphology codes of the
observed cancers among HIV-infected persons.
Discussion
This study is the first to use record linkage analysis to
estimate cancer incidence among PLWA in West Africa.
Among the ADCs, only KS was significantly increased
among HIV positive persons and there was no statistically
significant increase in incidence of NHL, CC and NADCs.
These results for KS and CC are consistent with the
findings from studies conducted in other countries
where increased risk of KS among HIV positive persons
and no association between CC and HIV was found
[24-26]. Although several studies suggest that the burden
of NHL is increased among HIV positive persons in
Africa [12,13,27,28], studies from West Africa have not
supported this, just like our results. Similar to Bolarinwa
et al., we identified several cases of NHL in the general
population but none of these were matched in the HIV
registry [18].
The relatively low incidence of cancers among HIV
positive persons in Nigeria is probably multifactorial.
An important possibility may be due to lack of cancer
diagnosis. Given the size of the HIV/AIDS epidemic and
main focus to diagnose and treat HIV or roll out preven-
tion programs, care providers may miss clinical features
suggestive of cancer in persons with HIV infection or
fail to investigate those clients thoroughly. Although
not well documented, our causal impression is that some
physicians who are concerned about occupational exposure
to HIV may provide limited quality services to HIV
positive persons [29,30]. Finally, the infrastructure to
d i a g n o s e ,r e f e r ,a n dr e g i s t e rp a t i e n t sm a ya l s oh a v e
caused low levels of utilization of diagnostic procedures
needed to confirm cancer diagnosis in PLWA [29].
There is some evidence that ascertainment of cancer
by the ABCR may not be complete. For example, the
Kampala Cancer Registry, which covers a population of
about 2.1 million, registered 4235 cancer cases during
2007 - 2009 [31]. ABCR, which covers a population of
about 1.4 million, registered 1815 cancer cases from
2009–2011 registered. This may be due to a longer
experience with cancer registration resulting in more
complete data or a lifestyle with a higher cancer risk
profile in Uganda. We also note that the HIV prevalence
is higher in Kyadondo compared to Abuja, 15% and
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Reference Study type Study population Study period Key findings
Ocheni (2004) [14] Case series University College Hospital, Ibadan, Nigeria Oct 2001 – June 2002 KS prevalence =0.01%
n=6; age range =29-35; m:f= 1:1.4 CC prevalence= 0.01%
NHL prevalence= 0.02%
Cisse (2007) [15] Case series Hôpital du Point G, Bamako, Mali Oct 2004 – Sept 2005 KS prevalence =1.6%
n=37; mean age=39.5; m:f=1:1
Ibekwe (2011) [16] Case series University college hospital Ibadan, Nigeria Oct 2008 - Sep 2009 KS prevalence =0.5%
n=13; age range=26 – 56; m:f =1:1
Abdus-Salam (2006) [17] Case series University college hospital Ibadan, Nigeria 2005- 2007 CC prevalence= 2.7%
n=6
Bolarinwa (2009) [18] Case series Obafemi Awolowo university teaching hospital, Ile-Ife, Nigeria Jan 1993 – Aug 2008 NHL= 1.5%
n=9; age range=24 – 60; m:f =1:1
Chu (2010) [19] Case series 3 primary care HIV clinics, Khayelitsha, Cape town, South Africa May 2001 – Jan 2007 KS prevalence =2.4%
n=189; age IQR= 29 – 41; m:f= 1.4:1
Iregbu (2006) [20] Case series National hospital Abuja, Nigeria Jan 2002 – July 2005 KS prevalence =0.8%
n =15; age=20–49; m:f= 2:1
Sitas (2000) [13] Case–control Chris Hani-Baragwanath, Hillbrow, New Johannesburg Hospitals, South Africa 1995 – 1999 KS*= 21.9 (12.5, 38.6)
n CC =167; n KS=89; n=NHL=23 NHL*= 5.0 (2.7-9.5)
CC*= 1.6 (1.1-2.3)
Stein (2008) [21] Case–control Chris Hani Baragwanath, Hillbrow & New Johannesburg Hospitals,
Johannesburg, South Africa
Mar 1995–June 2004 Age group 18 – 34 only
n CC =167; n KS=89; n NHL= 50 KS*= 58.6 (27.6, 124.5)
Age range=18 – 55
+ NH*= 6.6 (3.7, 12.0)
CC*= 1.5 (0.9, 2.4)
Mbulaiteye (2006) [12] AIDS cancer registry match Kampala cancer registry and AIDS support organization, Kyadondo, Uganda Oct 1998 – Dec 2002 KS
# =6.4 (4.8-8.4)
Number of incident cancers= 137; age IQR=25-35 NHL
# =6.7 (1.8-17)
CC
# =2.4 (1.1-1.4)
Chaabna (2011) [22] Population-based
cancer registries
Kyadondo, Uganda; Harare, Zimbabwe; Setif, Algeria; Sousse, Tunisia;
and Gharbiah Egypt
1998 - 2002 KS
P=<0.3– 26.3/100,000
CC
P=<8-34.8/100,000
NHL
P=2.4 – 11.9/100,000
n = number of cases with HIV; m: f= male: female; *OR and 95% confidence interval;
#SIR and 95% confidence interval;
PIncidence.
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18.6%, respectively [12,32], which may lead to a higher
burden of HIV-associated cancers, such as KS in Uganda.
In this regard, it is worth noting that the prevalence of
human herpesvirus 8 is lower in Nigeria compared to
Uganda [33], which would also explain the lower preva-
lence of cancer in ABCR, particularly KS. Our study high-
lights the opportunity to improve case finding methods
of cancer registries in Nigeria. Similar to other countries
in Africa, the infrastructure for population-based cancer
registries is poorly developed and not fully linked to
the HIV screening and registration process. Increased
utilization of electronic medical records and databases,
improved collaboration between registries and a multi-
disciplinary approach to data collection and management
will improve case ascertainment of HIV and cancer cases,
their report to registries and the linkage of registry
data. A separate study evaluating the completeness of
data obtained by the ABCR is under way.
Other possible explanations for the low cancer incidence
include the availability of HAART, which would be associ-
ated with improved immune function and reduced
risk of AIDS-associated cancers, such as KS [34,35].
The coverage of HAART in HIV positive persons in
Nigeria is relatively low (24% of individuals who should
be on HAART [36]), thus the contribution of this factor
is uncertain. Loss to follow-up is another possible ex-
p l a n a t i o n[ 3 6 ] ,a si sc o m p e t i ng mortality from common
diseases, such as tuberculosis and malaria.
Our study is also limited by the small sample size thus
we were unable to compare prevalent versus incident
cancers and we lacked sufficient power to detect small
differences that may exist between the general population
and the HIV positive population. Another limitation is
lack of unique individual personal identification numbers,
such as social security numbers, which would increase
the specificity and accuracy of the match. Nevertheless,
thorough clerical review of the linked records increased
our confidence in the matched records in study.
Additional research is needed to understand and improve
the specificity of matches in resource-limited settings,
where unique individual identification numbers are gener-
ally lacking. As the HIV positive population in Nigeria
continues to age, coverage with HAART improves and
the registry systems are strengthened, more record
linkage studies to examine the growing public health
impact of cancers occurring in people living with
HIV/AIDS will be warranted.
HIV Registry Cancer Registry
n=18929 n=2104
Excluded from analyses Excluded from analyses
n=1103 n=75
Record Linkage
HIV Registry n= 17826
Cancer Registry n=2029
Figure 1 Participants flow chart.
Table 2 Baseline characteristics of persons registered
with the Institute of Human Virology Nigeria (IHVN)
HIV registry
Characteristics HIV registry (N=17,826)
Sex, n (%)
Male 7,246 (41)
Female 10,580 (59)
Age (years), n (%)
0 – 14 1,389 (8)
15 – 24 1,237 (7)
25 – 34 6,980 (39)
35 – 44 5,567 (31)
45 – 54 2,091 (12)
55 – 64 476 (2.5)
65+ 86 (0.5)
Median age at diagnosis, IQR (years) 33 (27–40)
Calendar year of registration, n (%)
2005 3,336 (18)
2006 4,409 (25)
2007 3,017 (17)
2008 2,414 (14)
2009 2,025 (11)
2010 1,134 (6)
2011 833 (5)
2012 658 (4)
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We used record-linkage analysis to evaluate AIDS-defining
cancers in Nigeria and provide insights about their risk.
Consistent with the findings from other studies, the
risk of Kaposi Sarcoma but not Cervical Cancer or Non-
Hodgkin’s Lymphoma, was significantly increased among
HIV positive persons, compared to the general population
in Sub-Saharan Africa. Further studies are required to
more thoroughly examine the relationship between
cancers and HIV in West Africa and its determinants.
Methods
Study population
Abuja where this study was conducted is Nigeria’s Federal
Capital Territory, it had a population of 1.4 million in
2006 [37]. Because of its role as the capital of Nigeria,
individuals from all the country’s ethnic groups, tribes
and religions live there. Muslims make up approximately
50% of the population, Christians 40%, while the remain-
der adhere to indigenous beliefs. Abuja has five districts
and several surrounding towns and villages. The estimated
HIV prevalence in Abuja FCT was 8.6% in 2010, the fifth
highest in Nigeria [32].
HIV registry
The study population is a cohort of 18,929 HIV positive
persons, who were registered at the Institute of Human
Virology Nigeria (IHVN) HIV Care and Treatment pro-
grams in Abuja, Nigeria between 2005 and 2012. The IHVN
HIV cohort was established in 2005, and has accrued ~2,000
new clients per year on average, of whom the majority
(>90%) have Abuja as their permanent address. Upon
registration, each person is given a unique HIV cohort
identification number, in addition to the hospital number.
Information on age, date of birth, first name and last name,
sex, marital status, educational level, occupation, address
(street/city/state) and phone number are obtained. In
addition, anthropometric measurements and physical ex-
aminations are performed, biologic samples are collected
for quantitative and qualitative tests and referrals to appro-
priate departments are made when indicated. More than
90% of the clients have complete demographic information.
Cancer registry
Abuja Cancer Registry (ABCR) is a population based
cancer registry established in 2009. It covers the popula-
tion of Abuja where majority of its clients (>97%) per-
manently reside. National Hospital Abuja (NHA), which
is located in one of Abuja’s main districts, and University
of Abuja Teaching Hospital (UATH), which is located in
the main suburban district of Abuja are the main
sources of data for the ABCR. Other ABCR data sources
include public and private hospitals, and free-standing
pathology laboratories in Abuja. Cancer registrars visit
the data sources once a month to perform medical chart
abstraction and identify new cases of cancer diagnosed
during the month. For each new case, hospital number,
first and last names, age and date birth, sex, tribe,
address, date of diagnosis, tumor site and histology are
collected.
Registry linkage
The registry linkage was performed with a probabilistic
matching algorithm, using the software for automated
linkage in Italy (SALI) software. SALI is a software
designed for a linkage analysis of small registries, with
few expected linked cases [38]. Files with first name, last
name, sex, date of birth and HIV or cancer registration
numbers were provided by each registry and used for the
linkage analysis. The names were edited by deleting titles,
Table 3 Spectrum of observed cancers and standardized incidence ratios for HIV-infected persons
Cancer type ICD code Morphology code N (%) Incidence/100,000 person years
Crude rate SIR (95% CI)
AIDS defining cancers
Kaposi sarcoma C46 9140 8 (21) 4.9 5.7 (4.1, 7.2)
Cervical cancer C53 8070 8 (21) 7.8 2.0 (0.4, 3.5)
Non AIDS defining cancers
Anus C21 8010 1 (2) 0.6 0.3 (0, 17.8)
Liver C22 8170, 8174 3 (8) 1.8 0.5 (0, 5.1)
Other non-epithelial skin C44 8070 3 (8) 1.8 4.0 (0, 8.5)
Breast C50 8010, 8521 9 (23) 8.8 1.6 (0.2, 3.0)
Ovary C56 8010, 8310 2 (5) 2.0 3.6 (0, 20.1)
Prostate C61 8010 1 (2) 0.6 0.4 (0, 16.9)
Eye C69 8052 1 (2) 0.6 1.5 (0, 18.1)
Other, non-specified 8001 3 (8) 1.8 0.5 (0, 4.7)
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spelling in order to improve match sensitivity. The registry
linkage was conducted in collaboration with the devel-
opers of SALI. Linkage was done by researchers who were
independent of the HIVand cancer registries. To ascertain
the validity of the linkage analysis, an extensive review
of the medical records was conducted, to confirm the
identifiers and diagnosis on all matched cases.
Statistical analysis
Descriptive analyses were performed to characterize the
demographic attributes of the clients in the IHVN and
ABCR registries. Cancer incidence rates among HIV
positive persons, were estimated by dividing the number
of cancers by person-years of follow-up. In addition, we
categorized cancers in persons with HIV or AIDS occur-
ring 60 months before to 3 months after registration at
IHVN’s HIV treatment and prevention sites as prevalent;
cancers occurring 4 to 27 months after registration as
early-incident; and cancers occurring 28 months after
registration as late-incident cancers [12]. Standardized
incidence ratios (SIRs), a ratio of the number of cancers
observed among subjects, to the number of cancers
expected, were estimated and used to evaluate the asso-
ciation of various cancers with HIV infection in the
incident period. The number of expected cases for each
cancer type was calculated as a sum of the product of
person-time of HIV positive clients and the corresponding
sex, age and period specific cancer rates from the ABCR.
The source of the population count was Nigeria’s National
Population Council (NPC) data, which is stratified by age,
sex and geographic location [37]. As in the Ugandan
record-linkage study, we considered cancers to be as-
sociated with HIV infection if SIRs were significantly
increased in the incident period [12]. Statistical analyses
were performed with SAS for UNIX statistical software
(version 9.2; SAS Institute).
Consent
Written informed consent was obtained from the patient
for the publication of this report and any accompanying
images.
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